Why the study?
The study aimed to predict the preventive effect of clopidogrel against recurrent cardiovascular events among Arabs carrying CYP2C19 mutations and determine CYP2C19 allele and genotype frequencies.
Does carrying CYP2C19*2 or *3 mutations increase the risk of recurrent cardiovascular events in Arab patients receiving clopidogrel?
Population
Arab CVD patients using clopidogrel as secondary prophylaxis
Comparison
Carriers vs non-carriers of CYP2C19 alleles
Design
Systematic review and meta-analysis
Authors
Loading...
CYP2C19*2/*3 carriers show higher recurrent CVE risk on clopidogrel; extends evidence to Arabs but leaves genotype-guided alternatives open pending trials.
Does carrying CYP2C19*2 or *3 mutations increase the risk of recurrent cardiovascular events in Arab patients receiving clopidogrel?
Arab patients carrying CYP2C19*2 and *3 alleles have an approximately threefold increased risk of recurrent cardiovascular events when treated with clopidogrel compared to non-carriers.
Alkattan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: